Boothbay Fund Management’s Praxis Precision Medicines PRAX Stock Holding History

Boothbay Fund Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.04M	Buy	+6,100	New	+$1.93M	0.03%	710
2025 Q4	–	Sell	-56,400	Closed	-$2.99M	–	2269
2025 Q3	$2.99M	Sell	56,400 -32,500	-37%	-$1.58M	0.04%	464
2025 Q2	$3.74M	Buy	+88,900	New	+$3.39M	0.07%	359
2024 Q3	–	Sell	-92,100	Closed	-$3.81M	–	1860
2024 Q2	$3.81M	Buy	92,100 +86,300	+1,488%	+$4.08M	0.09%	301
2024 Q1	$354K	Buy	+5,800	New	+$260K	0.01%	1140
2022 Q3	–	Sell	-953	Closed	-$35K	–	2530
2022 Q2	$35K	Buy	+953	New	+$102K	﹤0.01%	2122

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Boothbay Fund Management's PRAX Position: Q2 2026 in Review

Boothbay Fund Management increased its Praxis Precision Medicines (PRAX) stake by 2.2% in Q2 2026, buying an estimated $121K and bringing the position to 17,968 shares worth $6.02M. The position accounts for 0.08% of the portfolio, ranked #292.

Boothbay Fund Management first reported a position in PRAX in Q3 2021 and has held it in 13 quarters since. The position peaked at $6.18M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Boothbay Fund Management held 17,968 shares of Praxis Precision Medicines worth $6.02M as of Q2 2026.
Boothbay Fund Management bought 381 Praxis Precision Medicines shares in Q2 2026, an estimated $121K.
Praxis Precision Medicines made up 0.08% of Boothbay Fund Management's portfolio in Q2 2026, its #292 holding.
Boothbay Fund Management first reported a position in Praxis Precision Medicines in Q3 2021 and has held it in 13 quarters since.
Boothbay Fund Management's Praxis Precision Medicines position peaked at $6.18M in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.